Health Blueprint

Back to Longevity News

News summary

Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications

Source: BioSpace - Funding • Published: 30 Oct 2026, 12:00

Summarized by Masters of Longevity from BioSpace - Funding.

Setara closed a $90 million Series A to advance STAR-0871 into patient trials.

Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications
Key Takeaways
  • Setara closed a $90 million Series A financing round.
  • STAR-0871 is a clinical-stage oral TRPV4 inhibitor advancing to patients.
  • STAR-0871 has received multiple FDA expedited development designations.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.